“As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard S. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.Ĭheckmate’s lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist delivered in a virus-like particle. (NASDAQ: CMPI) a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, today announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock.
(NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. and CAMBRIDGE, Mass., Ap(GLOBE NEWSWIRE) - Regeneron Pharmaceuticals, Inc.
#REGENERON CHECKMATE SKIN#
Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates
0 kommentar(er)
